ES2839453T3 - Métodos para el tratamiento de enfermedades colestásicas y fibróticas - Google Patents

Métodos para el tratamiento de enfermedades colestásicas y fibróticas Download PDF

Info

Publication number
ES2839453T3
ES2839453T3 ES17710285T ES17710285T ES2839453T3 ES 2839453 T3 ES2839453 T3 ES 2839453T3 ES 17710285 T ES17710285 T ES 17710285T ES 17710285 T ES17710285 T ES 17710285T ES 2839453 T3 ES2839453 T3 ES 2839453T3
Authority
ES
Spain
Prior art keywords
fibrosis
ntz
compound
cholestatic
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17710285T
Other languages
English (en)
Spanish (es)
Inventor
Raphaël Darteil
Robert Walczak
Carole Belanger
Emilie Negro
Pierre Daubersies
Philippe Delataille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Application granted granted Critical
Publication of ES2839453T3 publication Critical patent/ES2839453T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
ES17710285T 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades colestásicas y fibróticas Active ES2839453T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11
PCT/EP2017/055878 WO2017178172A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (1)

Publication Number Publication Date
ES2839453T3 true ES2839453T3 (es) 2021-07-05

Family

ID=55755536

Family Applications (3)

Application Number Title Priority Date Filing Date
ES20194454T Active ES2928408T3 (es) 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades fibróticas
ES17710285T Active ES2839453T3 (es) 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades colestásicas y fibróticas
ES20194458T Active ES2935185T3 (es) 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades fibróticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES20194454T Active ES2928408T3 (es) 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades fibróticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20194458T Active ES2935185T3 (es) 2016-04-11 2017-03-13 Métodos para el tratamiento de enfermedades fibróticas

Country Status (24)

Country Link
US (7) US20170290812A1 (ro)
EP (3) EP3777854B1 (ro)
JP (1) JP6894923B2 (ro)
KR (1) KR102431257B1 (ro)
CN (1) CN109069648B (ro)
AU (1) AU2017249602B2 (ro)
CA (1) CA3019399A1 (ro)
DK (2) DK3442580T3 (ro)
EA (2) EA202191466A1 (ro)
ES (3) ES2928408T3 (ro)
HR (1) HRP20201954T1 (ro)
HU (2) HUE052886T2 (ro)
IL (1) IL262052B (ro)
LT (1) LT3442580T (ro)
MD (1) MD3442580T2 (ro)
MX (1) MX2018012287A (ro)
MY (1) MY195437A (ro)
PH (1) PH12018502142A1 (ro)
PL (1) PL3442580T3 (ro)
PT (2) PT3442580T (ro)
SG (2) SG11201808402RA (ro)
SI (1) SI3442580T1 (ro)
WO (1) WO2017178172A1 (ro)
ZA (1) ZA201807389B (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
EP3442952A1 (en) * 2016-04-11 2019-02-20 Genfit Methods of treatment of cholestasis and fibrosis
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
JP7298928B2 (ja) * 2017-03-21 2023-06-27 ノヴァリード ファーマ インク ホスホジエステラーゼの阻害及びその関連障害のための治療剤
US11547699B2 (en) 2017-11-17 2023-01-10 Hubert Köster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
CA3153784A1 (en) 2019-10-28 2021-05-06 Nicolas STANKOVIC-VALENTIN Combination therapy of elafibranor and nitazoxanide having antioxident properties
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
CA3196479A1 (en) * 2020-11-17 2022-05-27 Philippe Delataille Methods of treatment of liver failure
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
CN116077502A (zh) * 2021-11-05 2023-05-09 广州市妇女儿童医疗中心 叶酸在预防、诊断和治疗遗传性、感染性或过敏性疾病中的应用
WO2024074515A1 (en) * 2022-10-04 2024-04-11 Genfit Nitazoxanide for the treatment of hepatic impairment

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
CN1898221A (zh) 2003-09-06 2007-01-17 沃泰克斯药物股份有限公司 Atp－结合弹夹转运蛋白的调控剂
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
EP2540296A1 (en) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1971594A2 (en) 2005-11-21 2008-09-24 Biogen Idec MA Inc. Substituted pyrazalones
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
JP5676258B2 (ja) 2007-08-03 2015-02-25 ロマーク ラボラトリース，エル．シー． アルキルスルホニル置換チアゾリド化合物
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
CN101903026B (zh) 2007-09-18 2013-05-08 斯坦福大学 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
JP5918124B2 (ja) 2009-05-12 2016-05-18 ロマーク ラボラトリーズ エル．シー． ハロアルキルヘテロアリールベンズアミド化合物
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
JP5779799B2 (ja) 2009-11-16 2015-09-16 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド ２’−フルオロ−６’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
BR112013029505A2 (pt) 2011-05-16 2020-01-07 Romark Laboratories L.C. Composição farmacêutica, e, uso de um composto
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
EP3442952A1 (en) 2016-04-11 2019-02-20 Genfit Methods of treatment of cholestasis and fibrosis
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
KR102410951B1 (ko) 2016-04-11 2022-06-20 장피트 담즙정체성 및 섬유증 질환의 치료 방법

Also Published As

Publication number Publication date
US10130613B2 (en) 2018-11-20
LT3442580T (lt) 2020-12-28
EA202191466A1 (ru) 2021-12-31
BR112018069684A2 (pt) 2019-01-29
CN109069648A (zh) 2018-12-21
US20180092885A1 (en) 2018-04-05
US20170290812A1 (en) 2017-10-12
MY195437A (en) 2023-01-20
SG11201808402RA (en) 2018-10-30
US20180092886A1 (en) 2018-04-05
MD3442580T2 (ro) 2021-04-30
PT3442580T (pt) 2020-12-23
JP2019513761A (ja) 2019-05-30
EP3777855B1 (en) 2022-10-19
US10130612B2 (en) 2018-11-20
HRP20201954T1 (hr) 2021-02-05
US20180085354A1 (en) 2018-03-29
IL262052B (en) 2021-12-01
DK3777855T3 (da) 2023-01-09
EP3442580B1 (en) 2020-09-23
KR102431257B1 (ko) 2022-08-10
ZA201807389B (en) 2020-01-29
KR20180129934A (ko) 2018-12-05
PT3777855T (pt) 2023-01-10
MX2018012287A (es) 2019-02-07
US20200316031A1 (en) 2020-10-08
EP3777854A1 (en) 2021-02-17
US20180092884A1 (en) 2018-04-05
HUE060671T2 (hu) 2023-04-28
CA3019399A1 (en) 2017-10-19
PH12018502142A1 (en) 2019-07-29
EP3777854B1 (en) 2022-07-20
CN109069648B (zh) 2022-01-14
SI3442580T1 (sl) 2021-01-29
ES2935185T3 (es) 2023-03-02
DK3442580T3 (da) 2020-12-21
US10117856B2 (en) 2018-11-06
ES2928408T3 (es) 2022-11-17
EA201892298A1 (ru) 2019-04-30
EP3442580A1 (en) 2019-02-20
US10117855B2 (en) 2018-11-06
SG10202004425XA (en) 2020-06-29
US11103484B2 (en) 2021-08-31
WO2017178172A1 (en) 2017-10-19
JP6894923B2 (ja) 2021-06-30
US20190000813A1 (en) 2019-01-03
HUE052886T2 (hu) 2021-05-28
AU2017249602B2 (en) 2022-06-16
IL262052A (en) 2018-11-29
EP3777855A1 (en) 2021-02-17
AU2017249602A1 (en) 2018-10-18
PL3442580T3 (pl) 2021-04-06

Similar Documents

Publication Publication Date Title
ES2839453T3 (es) Métodos para el tratamiento de enfermedades colestásicas y fibróticas
AU2017249603B2 (en) Methods of treatment for cholestatic and fibrotic diseases
US10905680B2 (en) Methods of treatment for cholestatic and fibrotic diseases
US20220323422A1 (en) Methods of treatment for cholestatic and fibrotic diseases
US10653678B2 (en) Methods of treatment for cholestatic and fibrotic diseases
EA040800B1 (ru) Способы лечения холестатического заболевания
BR112018069684B1 (pt) Uso de um composto selecionado do grupo que consiste em nitazoxanida (ntz) ou tizoxanida (tz) ou tizoxanida glucuronida (tzg) ou um sal farmaceuticamente aceitável de ntz, tz ou tzg
EA043787B1 (ru) Применение комбинации нитазоксанида или тизоксанида со статином для лечения холестатических и фибротических нарушений